Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain
about
Bioconcentration, metabolism and excretion of triclocarban in larval Qurt medaka (Oryzias latipes)Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effectsSoluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesImpact of soluble epoxide hydrolase and epoxyeicosanoids on human healthSoluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociceptionOptimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacyThe role of long chain fatty acids and their epoxide metabolites in nociceptive signalingMammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolaseStabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancerPossible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disordersTargeting epoxides for organ damage in hypertensionThe 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic painEpoxyeicosanoid signaling in CNS function and diseaseSoluble epoxide hydrolase in atherosclerosisIn vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolitesOmeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain modelPeripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptiveEpoxides and soluble epoxide hydrolase in cardiovascular physiologyPharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogsPotent natural soluble epoxide hydrolase inhibitors from Pentadiplandra brazzeana baillon: synthesis, quantification, and measurement of biological activities in vitro and in vivo11,12-Epoxyeicosatrienoic acid induces vasodilator response in the rat perfused mesenteric vasculature.An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension.Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids.The role of epoxide hydrolases in health and disease.Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP.Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors.Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies.Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures.The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment.Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain.Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeysAcute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency.Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex.Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order BrassicalesRegulation of avoidant behaviors and pain by the anti-inflammatory tyrosine phosphatase SHP-1.Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models
P2860
Q23918894-F8569767-4C42-4206-974A-9B9C3A0E83CAQ23918896-280F432A-FEA8-4B9D-8882-EADB52C314C4Q24597172-C1FB9B6D-9FF5-4DF4-B95C-7BDAE192F1B7Q24618018-31A6E254-C085-4B9C-AA0B-D05AE75BE65DQ24628660-6CAA3024-9324-4579-A5E5-6285951D2AA6Q27684895-F7B7C0E8-876E-46E0-9491-99E05862EB8EQ28248377-C65BD4C1-254C-4086-8FA6-5CB7CEDED989Q28302779-DF787A57-5984-4D3F-B881-F3B7259014AFQ28304230-81E788FA-4141-437B-8127-518AB1932A48Q28386662-065D2FA6-0DA3-461B-BD8A-82235E6F559DQ28387558-2DA74892-D482-451C-9124-F1E713FFD891Q28392416-53785C13-40ED-4603-A0FE-C739698A154CQ28394441-BB9003E7-42EE-4D73-8246-34C9B7AA5735Q28395004-BC614A9B-6D7A-426E-AFD8-639915EDB299Q28395228-334B5848-C5C3-487E-AA74-8DF44D401FB8Q28395323-3A108D0F-3D9B-4FCC-A0F8-048F88233BF2Q28396233-670101D5-45B7-43FC-9C74-7B98D56D906BQ28396313-3525D3AE-A201-4180-A13B-391046B3B19BQ28396888-F5D4F266-3F92-44B7-B138-E029ED952542Q28543232-9EC8A1D0-6943-4AC0-9161-B664F11A7008Q33578326-F0C1F7F7-8287-4217-9CC6-55EE7A03443DQ33882374-E467EE7D-52A4-41CB-935F-A3202D336DB0Q34115301-B5F01ADF-6A21-4B09-B586-13AD954A6D2FQ34287840-6E11849C-A43D-459D-938B-5A6FF3F056A0Q34440084-871CA51E-414E-4F87-8154-D9E252DB2FA5Q34720827-0BD26BD2-FCBD-4DB0-BCB1-2F207BF858EAQ34836888-47CC670C-4EA3-4145-BF8A-B01F740F211AQ35030893-5BEF1D9F-859B-4C95-9AF5-FFE6D720AD1BQ35069446-38023A6E-A1C3-4A3F-B409-906CD0EC6DC1Q35196023-79624F04-7529-4724-961C-E034C34DD6E6Q35543421-45D4AD12-098E-425F-9ECC-8F812DADD98AQ35895730-3B6A0B66-3C68-4EED-B3F2-1D12F123352AQ35987189-1E0BB3FF-8E22-4436-ADC3-A4F370DFAE12Q36024898-4826D961-B4D6-4AEA-96BF-BD74A2F7AD0CQ36094369-89EFA1E7-273A-46E5-BA20-322805799656Q36124088-A9E12BF6-7C2A-41F5-A542-42EA4196C422Q36202208-07F54819-ACD9-40B4-BE2C-D73D81F756ACQ36362984-98463004-4B0A-4D4A-9A0C-91C9CFB5AE24Q36426984-8985FC87-8B84-4D41-A9EC-443F307F00A0Q36625617-D728E39E-523B-4564-8BAF-7A7E5D0456AE
P2860
Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain
description
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im November 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/11/10)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/11/10)
@nl
наукова стаття, опублікована в листопаді 2006
@uk
مقالة علمية (نشرت في 10-11-2006)
@ar
name
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@ast
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@en
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@nl
type
label
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@ast
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@en
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@nl
prefLabel
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@ast
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@en
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@nl
P2093
P2860
P1433
P1476
Inhibition of soluble epoxide ...... rat model of inflammatory pain
@en
P2093
Bruce D Hammock
In Hae Kim
Kara R Schmelzer
Steven L Jinks
Troy Waite
P2860
P304
P356
10.1016/J.LFS.2006.07.031
P407
P577
2006-08-02T00:00:00Z